Purpose The C-X-C motif chemokine ligand 10 (CXCL10) participates in diabetes and diabetic cardiomyopathy development from the early stages. Rosiglitazone (RGZ) exhibits anti-inflammatory properties and can target cardiomyocytes secreting CXCL10, under interferon (IFN)gamma and tumor necrosis factor (TNF)alpha challenge. Cardiomyocyte remodeling, CD4 + T cells and dendritic cells (DCs) significantly contribute to the inflammatory milieu underlying and promoting disease development. We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFN gamma, TNF alpha, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFN gamma/TNF alpha-dependent signaling in human cardiomyocytes associated with chemokine release. Methods Cells maintained within an inflammatory-like microenvironment were exposed to RGZ at near therapy dose (5 mu M). ELISA quantified cytokine secretion; qPCR measured mRNA expression; Western blot analyzed protein expression and activation; immunofluorescent analysis detected intracellular IFN gamma/TNF alpha-dependent trafficking. Results In human CD4 + T cells and DCs, RGZ inhibited CXCL10 release likely with a transcriptional mechanism, and reduced TNF alpha only in CD4 + T cells. In human cardiomyocytes, RGZ impaired IFN gamma/TNF alpha signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release. Conclusion As the combination of Th1 biomarkers like CXCL10, IL-8, IL-6 with classical cardiovascular risk factors seems to improve the accuracy in predicting T2D and coronary events, future studies might be desirable to further investigate the anti-Th1 effect of RGZ.

Human cell-based anti-inflammatory effects of rosiglitazone / Sottili M, Filardi T, Cantini G, Cosmi L, Morano S, Luconi M, Lenzi A, Crescioli C. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - STAMPA. - 45:(2022), pp. 105-114. [10.1007/s40618-021-01621-5]

Human cell-based anti-inflammatory effects of rosiglitazone

Cantini G;Cosmi L;Luconi M;
2022

Abstract

Purpose The C-X-C motif chemokine ligand 10 (CXCL10) participates in diabetes and diabetic cardiomyopathy development from the early stages. Rosiglitazone (RGZ) exhibits anti-inflammatory properties and can target cardiomyocytes secreting CXCL10, under interferon (IFN)gamma and tumor necrosis factor (TNF)alpha challenge. Cardiomyocyte remodeling, CD4 + T cells and dendritic cells (DCs) significantly contribute to the inflammatory milieu underlying and promoting disease development. We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFN gamma, TNF alpha, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFN gamma/TNF alpha-dependent signaling in human cardiomyocytes associated with chemokine release. Methods Cells maintained within an inflammatory-like microenvironment were exposed to RGZ at near therapy dose (5 mu M). ELISA quantified cytokine secretion; qPCR measured mRNA expression; Western blot analyzed protein expression and activation; immunofluorescent analysis detected intracellular IFN gamma/TNF alpha-dependent trafficking. Results In human CD4 + T cells and DCs, RGZ inhibited CXCL10 release likely with a transcriptional mechanism, and reduced TNF alpha only in CD4 + T cells. In human cardiomyocytes, RGZ impaired IFN gamma/TNF alpha signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release. Conclusion As the combination of Th1 biomarkers like CXCL10, IL-8, IL-6 with classical cardiovascular risk factors seems to improve the accuracy in predicting T2D and coronary events, future studies might be desirable to further investigate the anti-Th1 effect of RGZ.
2022
45
105
114
Sottili M, Filardi T, Cantini G, Cosmi L, Morano S, Luconi M, Lenzi A, Crescioli C
File in questo prodotto:
File Dimensione Formato  
Sottili JEI2022.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.95 MB
Formato Adobe PDF
1.95 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1256596
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact